Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Hiroshi Kurahara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7735-9607; OpenAlex author ID A5009972099. Sources: OpenAlex.

Their work

Papers
48 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
110
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 7 papers · 2018: 5 papers · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers

Papers 48

  1. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  2. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  3. Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles. Co-author DOI 10.3389/fonc.2025.1682072↗
  4. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study. Co-author DOI 10.1016/j.eclinm.2024.102936↗
  5. Genetic Assessment of Intraductal Papillary Mucinous Neoplasm for Predicting Concomitant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002373↗
  6. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  7. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  8. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  9. Coronin 1C, Regulated by Multiple microRNAs, Facilitates Cancer Cell Aggressiveness in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/genes14050995↗
  10. Value of Dual-Energy Computed Tomography for Detecting Small Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002207↗
  11. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. Co-author DOI 10.21873/anticanres.15824↗
  12. Metastasis Suppressor Genes in Pancreatic Cancer: An Update. Co-author DOI 10.1097/mpa.0000000000001853↗
  13. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-021-09712-6↗
  14. Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15297↗
  15. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. First author DOI 10.3390/cancers13051057↗
  16. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.015↗
  17. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning. Co-author DOI 10.1158/1078-0432.ccr-19-1247↗
  18. Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes. Co-author DOI 10.3390/cancers12102731↗
  19. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Co-author DOI 10.3390/ijms21186459↗
  20. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  21. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. Co-author DOI 10.1038/s10038-019-0584-6↗
  22. Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-07098-6↗
  23. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. Co-author DOI 10.3390/cancers11030327↗
  24. Corrigendum to "Clinical impact of circulating tumor cells and therapy response in pancreatic cancer" [43 (6) (2017) 1050-1055]. Co-author DOI 10.1016/j.ejso.2018.03.015↗
  25. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Co-author DOI 10.1097/mpa.0000000000001066↗
  26. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Co-author DOI 10.1111/cas.13610↗
  27. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6357-1↗
  28. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3… Co-author DOI 10.18632/oncotarget.25599↗
  29. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. First author DOI 10.1007/s10585-017-9840-3↗
  30. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.01.241↗
  31. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.07.191↗
  32. MicroRNA in pancreatic cancer. First author DOI 10.1038/jhg.2016.59↗
  33. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13119↗
  34. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18261↗
  35. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Co-author DOI 10.18632/oncotarget.19591↗
  36. Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Co-author DOI 10.1002/ijc.30110↗
  37. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. Co-author DOI 10.1007/s00268-016-3477-2↗
  38. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Co-author DOI 10.1016/j.pan.2015.09.015↗
  39. Assessment of percutaneous laparoscopic ultrasonography-guided core needle biopsy for the advanced diagnosis of unresectable pancreatic cancer. Co-author DOI 10.6092/1590-8577/2891↗
  40. [Radiotherapy for metastatic lesion of pancreatic cancer]. Co-author PMID 25857007↗
  41. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pa… Co-author DOI 10.1097/mpa.0b013e318254f2d1↗
  42. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. Co-author PMID 24393873↗
  43. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Co-author DOI 10.1002/jso.23020↗
  44. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00534-011-0400-y↗
  45. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2263-0↗
  46. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy]. Co-author PMID 22421785↗
  47. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. Co-author DOI 10.1016/j.jss.2009.05.026↗
  48. Advanced staging laparoscopy using single-incision approach for unresectable pancreatic cancer. Co-author DOI 10.1097/sle.0b013e31823bae57↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuko Mataki · 29 shared papers, 2011–2024 · strength 2.01
  2. Shoji Natsugoe · 30 shared papers, 2011–2020 · strength 1.80
  3. Kosei Maemura · 27 shared papers, 2011–2021 · strength 1.73
  4. Tetsuya Idichi · 16 shared papers, 2017–2024 · strength 1.70
  5. Takao Ohtsuka · 10 shared papers, 2019–2024 · strength 1.32
  6. Naohiko Seki · 11 shared papers, 2017–2023 · strength 1.02
  7. Yuto Hozaka · 6 shared papers, 2020–2024 · strength 0.79
  8. Hideyuki Oi · 3 shared papers, 2024–2025 · strength 0.53
  9. Satoshi Hirano · 3 shared papers, 2024–2025 · strength 0.50
  10. Hiroyuki Shinchi · 9 shared papers, 2012–2020 · strength 0.50
  11. Hiroaki Nagano · 3 shared papers, 2023–2025 · strength 0.46
  12. Kohei Nakata · 3 shared papers, 2023–2025 · strength 0.46
  13. Michiyo Higashi · 4 shared papers, 2013–2024 · strength 0.41
  14. Masafumi Nakamura · 3 shared papers, 2019–2025 · strength 0.38
  15. Yoshihiro Miyasaka · 3 shared papers, 2019–2025 · strength 0.38
  16. Kosuke Fukuda · 2 shared papers, 2023–2024 · strength 0.37
  17. Kenichi Hakamada · 2 shared papers, 2025 · strength 0.35
  18. Sohei Satoi · 2 shared papers, 2025 · strength 0.35
  19. Masaaki Hidaka · 2 shared papers, 2025 · strength 0.35
  20. Masamichi Mizuma · 2 shared papers, 2025 · strength 0.35
  21. Goro Honda · 2 shared papers, 2025 · strength 0.35
  22. Itaru Endo · 2 shared papers, 2025 · strength 0.35
  23. Naoto Yamamoto · 2 shared papers, 2024–2025 · strength 0.34
  24. Etsuro Hatano · 2 shared papers, 2024–2025 · strength 0.34
  25. Michiaki Unno · 2 shared papers, 2024–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.